AZD8529

DRUG6 trials

Sponsors

AstraZeneca, National Institute on Drug Abuse (NIDA)

Conditions

HealthyHealthy VolunteerMemory ImpairmentSchizophreniaTobacco Use Disorder

Early Phase 1

The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers

CompletedNCT00985933

AstraZenecaHealthy, Memory Impairment

Start: 2010-02-28End: 2011-04-30Target: 20Updated: 2011-05-04

Phase 1

AZD8529 Single Ascending Dose Study

CompletedNCT00755378

AstraZenecaHealthy Volunteer

Start: 2008-09-30End: 2009-03-31Target: 58Updated: 2009-03-26

AZD8529 Multiple Ascending Dose Study in Healthy Subjects

CompletedNCT00765492

AstraZenecaHealthy Volunteer

Start: 2008-10-31End: 2009-03-31Target: 47Updated: 2009-06-26

AZD8529 Single Ascending Dose Study in Healthy Japanese Subjects

CompletedNCT00886756

AstraZenecaHealthy

Start: 2009-04-30End: 2009-07-31Target: 48Updated: 2009-08-19

The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics

CompletedNCT00986531

AstraZenecaSchizophrenia

Start: 2009-11-30End: 2011-10-31Updated: 2011-11-01

Phase 2

The Study of AZD8529 for Smoking Cessation in Female Smokers

CompletedNCT02401022

National Institute on Drug Abuse (NIDA)Tobacco Use Disorder

Start: 2015-07-31End: 2017-01-31Updated: 2017-11-29